CAR T Cell Therapy in MDS/AML

#HEMEPATH Navigating Change and Integrating WHO 5th/ ICC Classification Systems in the diagnosis …Подробнее

The potential of bringing CAR-T therapy to MDS and challenges to overcomeПодробнее

Recent advances in CAR-T therapy for MDSПодробнее

Future prospects for CAR-T cell therapy in AMLПодробнее

EHA and ASCO 2023 highlights: promising treatments in AML, MDS, and ALLПодробнее

Novel Therapies in Myeloid NeoplasmsПодробнее

PRGN-3006 in the treatment of AML and MDSПодробнее

Stanford Pediatric Grand Rounds: Pediatric Acute Myeloid Leukemia: A Clinical ChallengeПодробнее

Addressing the major challenges to CAR-T therapy in AMLПодробнее

What's New in MDS May 19 2021Подробнее

Understanding CAR-T Cells - 11/15/18Подробнее

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDSПодробнее

Allogeneic CAR-NK cell therapy in R/R AML/MDSПодробнее

Transplant Outcomes in Older Adults with MDS and AML 2021Подробнее

Updates from ASH 2020: Promising Treatment Advances for MDS and AMLПодробнее

Refractory/Relapsed AML in ChildrenПодробнее

From MDS to AML: What Every Patient Needs to Know 11/28/17Подробнее

CAR-T - A Potential in Myeloid Cancers? - K CumminsПодробнее

Venetoclax and magrolimab for treatment of AML and MDSПодробнее